Dose-dense and dose-intense chemotherapy for small cell ovarian cancer: 2 cases and review of literature

被引:0
|
作者
Raj Kumar Shrimali
Peter Denzil Correa
Nick S. Reed
机构
[1] Beatson West of Scotland Cancer Centre,Department of Clinical Oncology
[2] University of Glasgow,Beatson West of Scotland Cancer Centre, Gartnavel General Hospital
来源
Medical Oncology | 2011年 / 28卷
关键词
Small cell cancer; Ovary; Chemotherapy; Surgery;
D O I
暂无
中图分类号
学科分类号
摘要
Small cell carcinomas of the ovary (SCCO) are rare and aggressive malignant neoplasms carrying a poor prognosis. Although multi-modality treatment including chemotherapy leads to a high initial response rate, the majority of these patients relapse quickly and die within 2 years of diagnosis. Because these tumours are rare, there is no consensus to support any particular approach to management. We present 2 cases and review the relevant literature to make a number of recommendations. The treatment of these unusual cases should to be individually discussed in a multi-disciplinary team and multi-modality treatment including surgery, chemotherapy and radiotherapy should be considered for patients with limited disease. Conservative, fertility-preserving surgery may be considered in younger women with early-stage disease. Induction chemotherapy with weekly dose-dense and dose-intense carboplatin and taxane is useful. Prophylactic cranial irradiation (PCI) may be considered in patients in remission after primary treatment with chemotherapy or surgery.
引用
收藏
页码:766 / 770
页数:4
相关论文
共 50 条
  • [31] Dose-dense paclitaxel for advanced ovarian cancer Reply
    Katsumato, Noriyuki
    LANCET, 2010, 375 (9711): : 281 - 281
  • [32] Dose-dense adjuvant chemotherapy for primary breast cancer
    Fornier, M
    Norton, L
    BREAST CANCER RESEARCH, 2005, 7 (02) : 64 - 69
  • [33] Current status of dose-dense chemotherapy for breast cancer
    Seidman, AD
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (Suppl 1) : S78 - S83
  • [34] Dose-dense chemotherapy as adjuvant treatment for breast cancer
    Atkins, CD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (04) : 749 - 750
  • [35] Dose-Dense Chemotherapy Regimen for Breast Cancer Associated with Significant Decline in Ovarian Reserve
    Chamani, Isaac J.
    Gannon, Alexandra
    Connell, Phillip T.
    Bisen, Ajit
    Kovanci, Ertug
    Sangi-Haghpeykar, Haleh
    Woodard, Terri
    McKenzie, Laurie J.
    JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, 2024, 13 (03) : 465 - 468
  • [36] Dose-dense chemotherapy: A possible high cost-effectiveness treatment for ovarian cancer
    Huang, Chen-Yu
    Chang, Chia-Ming
    Wang, Peng-Hui
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2020, 59 (03): : 351 - 352
  • [37] Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy.
    Barron, R.
    Natoli, J. L.
    Miller, R. M.
    Lyman, G. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer
    Lyman, Gary H.
    Barron, Richard L.
    Natoli, Jaime L.
    Miller, Ross M.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 81 (03) : 296 - 308
  • [39] Dose-dense chemotherapy for breast cancer: the story so far
    C Hudis
    British Journal of Cancer, 2000, 82 : 1897 - 1899
  • [40] Dose-dense chemotherapy for breast cancer: the story so far
    Hudis, C
    BRITISH JOURNAL OF CANCER, 2000, 82 (12) : 1897 - 1899